Manufacturing & Packaging

The collaborative research initiative will be focused on advancing approaches to enhance the therapeutic efficacy of regulatory T cells and tumor-infiltrating lymphocytes.

The new system meets the increasing demand for faster, more precise processes that enhance quality while boosting efficiency in the pharma manufacturing industry.

The 200,000 square-foot Madison, WI facility will serve as the flagship location, with capabilities for future growth.

The biopharma company—whose US headquarters is in Atlanta—will be building a new biologics manufacturing facility in a city to be named at a later date.

The installation of the new vial, syringe, and cartridge line is expected to take place throughout the coming year.

The track-and-trace systems provider expands its life sciences portfolio by integrating the high-speed, adaptable ETF-300 precision labeler through a partnership that brings Industry 4.0-ready capabilities, advanced printing tech, and enhanced data security to pharmaceutical packaging.

The move bolsters the CDMO’s commitment to cell and gene therapy by incorporating advanced manufacturing and fill-finish capabilities.

As the adoption of biologics rises, demand for home healthcare grows, and conditions like diabetes and autoimmune disorders become more prevalent, self-injectables are here to stay.

The company’s branded form of nadofaragene firadenovec-vncg will also be produced at a hub in Parsippany, NJ.

The deal for the San Diego hub provides the CDMO with its first-ever North American manufacturing location for prefilled syringes and cartridges.

The new firm—with 13 manufacturing facilities spanning France, Sweden, and Spain—will support the pharma supply chain through to commercialization.

Vendors are growing, and product and service offerings are expanding.

When delays and disruptions threaten not only product integrity but patient well-being, thorough risk assessment and mitigation are essential.

Exploring the importance of contract development and manufacturing organizations in advancing the latest technology for effective delivery of temperature-sensitive medicines.

Taking stock of today's gains and tomorrow's potential for generative artificial intelligence in reshaping the industry.

New facility is expected to serve as a global hub for accelerating the development of next-generation antibody-drug conjugates for the treatment of cancer.

The parties aim to create an end-to-end digital thread that links research data all the way through to life sciences manufacturing.

The CRDMO’s acquisition of the Baltimore plant is expected to boost its biologics presence.

In the second part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Brad Stewart, BDO’s national life sciences co-leader, outlines the internal constraints that CFOs are reporting as their biggest manufacturing obstacle, along with other hurdles they are encountering.

In the second part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Jason C. Foster, CEO of Ori Biotech, comments on the primary factors causing manufacturing bottlenecks in the space, along with how the industry can overcome them in order to scale up production.

In the first part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Jason C. Foster, CEO of Ori Biotech, offers his perspective on the state of CGTs, along with their potential for transforming medicine.

This link in the pharma supply chain is undergoing a major transformation propelled by technological advancements, regulatory changes, and evolving market dynamics, requiring industry leaders to adopt innovative strategies in order to remain competitive.

In the first part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Brad Stewart, BDO’s national life sciences co-leader, discusses how the tariffs impact the reshoring of manufacturing services, alongside the strategies that pharma leaders can use in order to start shoring up their supply chains.

The US president delays tariffs that comply with the 2020 USMCA for one month, with reciprocal tariffs still expected to go into effect by April 2.

The news comes amid the possibility that President Trump imposes a 25% tariff on pharmaceuticals, which could encourage manufacturers to begin reshoring their services.